Clinical Trials
8 trialsNCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03110107 2025-04-24
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03936959 2025-01-15
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT02341625 2022-08-18
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT01394003 2019-01-18
A Study of LY2584702 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT01347866 2018-10-29
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Pfizer
Phase 1 Terminated
NCT00729833 2014-06-09
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated